ClinicalTrials.gg
CompletedNCT03137381Updated Jul 19, 2022Results posted

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

A Phase 2 interventional study of CTP-543 and CTP-543 matching placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
7th of 10
149 · median 336
Started
2017
the only one that year
Phase 2
4 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 1st registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.

Read the detailed description

This is a double-blind, randomized, placebo-controlled multi-center study consisting of 3 cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated sequentially in ascending dose order. Participants will be randomized to either an active dose of CTP-543 or placebo for a 24-week treatment period.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
  • Clinical lab results within the normal range

Exclusion criteria

Exclusion Criteria:

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
  • Treatment with systemic medications or biologics.
  • Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Cohort 1: CTP-543 4 mg BID

    Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Cohort 2: CTP-543 8 mg BID

    Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Cohort 3: CTP-543 12 mg BID

    Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.

    Drug: CTP-543

  • Placebo comparator
    Combined Placebo

    Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.

    Drug: CTP-543 matching placebo

Interventions

  • Administered as tablets.

  • DrugCTP-543 matching placebo

    Administered as tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Responders were defined as participants achieving at least a 50% relative reduction in SALT score from baseline at Week 24.

    Time frame: Week 24

  2. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAE is defined as any adverse event that occurs after administration of the first dose of study drug.

    Time frame: From first dose of study drug up to safety follow up at Week 28

07

Results

Posted Jul 19, 2022

Participant flow

Participants were enrolled at 13 study centers in the United States from 09 August 2017 to 08 July 2019.

Participant flow — Overall Study
MilestoneCombined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BID
Started44303837
Safety population44293836
Completed35233036
Not completed9781
Withdrew: Adverse event3020
Withdrew: Lost to follow-up2110
Withdrew: Protocol deviation1101
Withdrew: Withdrawal by investigator0110
Withdrew: Withdrawal by subject3430
Withdrew: Pregnancy0010

Outcome measures

PrimaryPercentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Responders were defined as participants achieving at least a 50% relative reduction in SALT score from baseline at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24
Percentage of participantsCombined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BID
Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 249.321.447.458.3
Statistical analysis
  • Combined Placebo vs Cohort 1: CTP-543 4 mg BID · Chi-squared · p = 0.177
  • Combined Placebo vs Cohort 2: CTP-543 8 mg BID · Chi-squared · p = <0.001
  • Combined Placebo vs Cohort 3: CTP-543 12 mg BID · Chi-squared · p = <0.001
PrimaryNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAE is defined as any adverse event that occurs after administration of the first dose of study drug.

Time frame:
From first dose of study drug up to safety follow up at Week 28
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsCombined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BID
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)31253130

Adverse events

Collected over From first dose of study drug up to safety follow up at Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combined Placebo0/44 (0%)0/44 (0%)31/44 (70.5%)
Cohort 1: CTP-543 4 mg BID0/29 (0%)0/29 (0%)25/29 (86.2%)
Cohort 2: CTP-543 8 mg BID0/38 (0%)0/38 (0%)31/38 (81.6%)
Cohort 3: CTP-543 12 mg BID0/36 (0%)1/36 (2.8%)30/36 (83.3%)
Most frequent serious events
Most frequent serious events
EventCombined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BID
CellulitisInfections and infestations0/440/290/381/36
Most frequent other events
Showing 10 of 39
Most frequent other events
EventCombined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BID
HeadacheNervous system disorders4/445/2910/387/36
NasopharyngitisInfections and infestations1/443/293/389/36
Upper respiratory tract infectionInfections and infestations7/442/292/387/36
AcneSkin and subcutaneous tissue disorders2/444/294/386/36
NauseaGastrointestinal disorders4/444/294/381/36
CoughRespiratory, thoracic and mediastinal disorders0/444/291/382/36
Low density lipoprotein increasedInvestigations0/440/294/380/36
FolliculitisInfections and infestations0/443/292/381/36
Blood creatine phosphokinase increasedInvestigations1/443/292/381/36
DiarrheaGastrointestinal disorders3/443/291/380/36

Baseline characteristics

Randomized population included all the randomized participants.

Age, Continuous
Age, Continuous(years)Combined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BIDTotal
Mean37.8 ± 13.5035.7 ± 11.0137.3 ± 14.1835.8 ± 12.3736.8 ± 12.85
Sex: Female, Male
Sex: Female, Male(Participants)Combined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BIDTotal
Female29222628105
Male15812944
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BIDTotal
Hispanic or Latino534315
Not Hispanic or Latino39263334132
Unknown or Not Reported01102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Combined PlaceboCohort 1: CTP-543 4 mg BIDCohort 2: CTP-543 8 mg BIDCohort 3: CTP-543 12 mg BIDTotal
American Indian or Alaska Native00000
Asian222410
Native Hawaiian or Other Pacific Islander10001
Black or African American727319
White33252630114
Other11305
08

Study locations

13 sites
  • University of California, Irvine
    Irvine, California 92697, United States
  • Contour Dermatology & Cosmetic Surgery Center
    Rancho Mirage, California 92270, United States
  • Stanford University School of Medicine
    Redwood City, California 94064, United States
  • Kaiser Permanente Northern California
    San Francisco, California 94118, United States
  • Yale School of Medicine
    New Haven, Connecticut 06519, United States
  • Siperstein Dermatology Group
    Boynton Beach, Florida 33472, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Icahn School of Medicine at Mt. Sinai
    New York, New York 10029, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Northwest Dermatology
    Portland, Oregon 97210, United States
  • Suzanne Bruce & Associates, PA
    Houston, Texas 77056, United States
09

References and documents

Publications

  • Cassella J, Hamilton C, von Hehn J, Braman V. JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata. In: Proceedings from the 2019 American Academy of Dermatology Meeting; 01-05 March 2019; Washington, DC. Abstract 11291.
  • Cassella J, Hamilton C, von Hehn J, Braman V. JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata. In: Proceedings from the 11th World Congress Hair Research; 24-27 April 2019; Sitges, Barcelona.
  • Cassella J, Hamilton C, von Hehn J, Braman V. CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate to severe alopecia areata. In: Proceedings from the 28th EADV Congress; 09-13 October 2019, Madrid, Spain. D3T01.1: Late breaking news.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2019, 22 months.

Results were first posted in Jul 2022, 3 years after primary completion. A results delay was requested in Jul 2020.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2017
First posted
May 2, 2017
StartActual
Aug 9, 2017
Primary completionActual
Jul 8, 2019
CompletionActual
Jul 8, 2019
Results delay requested
Jul 2, 2020
Results first posted
Jul 19, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03137381
Responsible party
Sponsor
First posted
May 2, 2017
Start date
Aug 9, 2017
Primary completion
Jul 8, 2019
Completion
Jul 8, 2019
Results posted
Jul 19, 2022
Last update
Jul 19, 2022

Study contacts

Colleen E. Hamilton
study director · Concert Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion